WAT · Earnings call · 2026Q2T · Full report
Pricing and Contract Compliance
WATERS CORP /DE/ · 2026-08-04 · Importance 51 · Surprise 50 · No source text
Waters established pricing directors and deal desks across the acquired Biosciences and Diagnostic Solutions businesses to improve discount control and contract compliance. The company achieved 90 basis points of net price realization in the second quarter, versus the historical 50 basis points embedded in its prior approach, and is targeting 150 basis points. Waters identified approximately 700 U.S. reagent-rental contracts as out of compliance and began remediation. Management expects renegotiation to improve pricing and accelerate adoption of new products.
Key facts
- Approximately 700 U.S. Diagnostic Solutions contracts identified as out of compliance and remediation efforts are underway
- Goal to achieve 150 basis points of price contribution in the acquired businesses
- Q2 2026 achieved 0.9% price realization in acquired business versus 0.5% embedded in prior guide; increasing to 0.9% for remainder of year
- Q2 2026 achieved 90 basis points of net price realization in the acquired businesses
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| margin | positive | contingent | +0.2% | Goal to achieve 150 basis points of price contribution in the acquired businesses |
| revenue | negative | probable | — | Approximately 700 U.S. Diagnostic Solutions contracts identified as out of compliance and remediation efforts are underway |
| revenue | positive | realized | — | Q2 2026 achieved 0.9% price realization in acquired business versus 0.5% embedded in prior guide; increasing to 0.9% for remainder of year |
| revenue | positive | committed | — | Q2 2026 achieved 0.9% price realization in acquired business versus 0.5% embedded in prior guide; increasing to 0.9% for remainder of year |